Peter Schmid, MD, PhD, on Early-Stage TNBC: Updated Survival Results From KEYNOTE-522
2023 SABCS
Peter Schmid, MD, PhD, of Queen Mary University of London and Barts Cancer Institute, discusses phase III findings from KEYNOTE-522 showing that neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab continues to show a clinically meaningful improvement in event-free survival compared with neoadjuvant chemotherapy alone in patients with early-stage triple-negative breast cancer (TNBC) (Abstract LBO1-01).
The ASCO Post Staff
Nicholas C. Turner, MD, PhD, of The Royal Marsden Hospital NHS Foundation Trust, and the Institute of Cancer Research, London, discusses the monarchE trial, which evaluated molecular profiling of archived primary tumor tissue from patients with hormone receptor–positive, HER2-negative, node-positive, high-risk early-stage breast cancer and its potential association with clinical outcomes. Adjuvant abemaciclib plus endocrine therapy (ET) maintained invasive disease–free survival benefit compared with ET alone across all molecular subtypes as measured by RNA sequencing (Abstract GS03-06).
The ASCO Post Staff
Barbara Pistilli, MD, of France’s Gustave Roussy, discusses a phase Ib analysis from the CAPItello-292 study, which showed capivasertib plus palbociclib plus fulvestrant was tolerable at all dose levels in heavily pretreated patients with hormone receptor–positive, HER2-negative advanced breast cancer. As data collection continues, evidence of clinical activity has been observed in patients treated with the recommended phase III dose (Abstract PS12-09).
The ASCO Post Staff
Oleg Gluz, MD, of the West German Study Group and Breast Center Niederrhein, discusses the impact of age and ovarian function suppression in response to preoperative endocrine treatment for both pre- and postmenopausal patients with early-stage breast cancer. He describes ways in which the outcome data of the ADAPTcycle study might influence clinical decisions (Abstract LBO1-05).
The ASCO Post Staff
Luca Gianni, MD, of Milan’s Fondazione Michelangelo, discusses findings from the APTneo Michelangelo trial, which showed that adding atezolizumab to chemotherapy and trastuzumab plus pertuzumab did not significantly increase the rate of pathologic complete response (pCR) in women with HER2-positive breast cancer. An exploratory analysis showed that adding atezolizumab to neoadjuvant anthracycline and cyclophosphamide followed by HPCT (trastuzumab + pertuzumab and chemotherapy) led to higher pCR rates than HPCT and atezolizumab (Abstract LBO1-02).
The ASCO Post Staff
Gabriel N. Hortobagyi, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from the NATALEE trial, which continued to demonstrate improved invasive disease–free survival with ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) over a NSAI alone in patients with hormone receptor–positive, HER2-negative early breast cancer (Abstract GS03-03).
